adnexa

(redirected from adnexus)
Also found in: Thesaurus, Medical, Encyclopedia.

ad·nex·a

 (ăd-nĕk′sə)
pl.n.
Accessory or adjoining anatomical parts, as ovaries and fallopian tubes in relation to the uterus.

[Latin, neuter pl. of adnexus, past participle of adnectere, to bind to; see annex.]

ad·nex′al adj.

adnexa

(ædˈnɛksə)
pl n
(Anatomy) anatomy adjoining organs, esp of the uterus
[C19: New Latin: appendages]
adˈnexal adj

ad•nex•a

(ædˈnɛk sə)

n.pl.
appended or accessory anatomical parts, as the eyelids in relation to the eyes.
[1895–1900; < Latin, neuter pl. of adnexus physically attached, joined, past participle of adnectere to attach; see ad-, nexus]
ad•nex′al, adj.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.adnexa - accessory or adjoining anatomical parts or appendages to an organ (especially of the embryo)adnexa - accessory or adjoining anatomical parts or appendages to an organ (especially of the embryo); "Fallopian tubes and ovaries are adnexa of the uterus"
body part - any part of an organism such as an organ or extremity
Translations

ad·nex·a

n., pl. anejos, anexos, apéndices tales como las trompas de Falopio.
References in periodicals archive ?
En seguida esta Facebook, con presencia en mas del 20% de las paginas, luego Twitter, Adnexus, Oracle y MediaMath.
Prior to BMS, from 2009 to 2011, Bechtold served as vice president, Strategic Operations at Adnexus Therapeutics.
[UKPRwire, Wed Jul 24 2013] Global Market Direct's pharmaceuticals report, "Adnexus Therapeutics, Inc.
Prior to Avila, Katrine was Vice President Business Development at Adnexus Therapeutics, a company developing a new class of protein therapeutics.
Previously, she was vice president Business Development at Adnexus Therapeutics.
Results for 2007 reflect the acquisition of Adnexus Therapeutics.
Some of the larger acquisitions of mAb producers by pharmaceutical companies this year were Bristol-Myers Squibb's purchase of Adnexus for $415 million in September and Roche's $56.5 million payout for Therapeutic Human Polyclonals in April.
In an effort to expand its cancer treatments, Bristol-Myers is acquiring developers of experimental medicines, such as Adnexus Therapeutics Inc., and has said it plans to seek approval by the end of the year for two other therapies, the bladder-cancer drug vinflunine and the melanoma medicine ipilimumab.